Features and expert interviews

Read our quick round-up of the LEAD trials of the daily injectable GLP-1 receptor agonist liraglutide in people with type 2 diabetes.

Read our quick round-up of the GetGoal trials of the daily injectable GLP-1 receptor agonist lixisenatide in people with type 2 diabetes.

We round up the medications currently approved for treating type 2 diabetes in children and adolescents and look at what agents are coming through clinical trials.

Why and how does ethnicity influence risk and management approach for pediatric type 2 diabetes? We talk to childhood obesity specialist Julian Hamilton-Shield.

Torsten Olbers puts the case for metabolic surgery as a treatment option for children with type 2 diabetes.

Read this Hot Topic Review to catch up on the latest research into the risks and benefits of fasting for people with diabetes.

Read our quick round-up of the DURATION trials of the weekly formulation of the GLP-1 receptor agonist exenatide in people with type 2 diabetes.

Read our quick round-up of the AWARD trials of the GLP-1 receptor agonist dulaglutide in people with type 2 diabetes.

What makes some people more likely than others to have suicidal thoughts? We outline the risk factors and circumstances that can play a role.

How frequent are suicide deaths in people with diabetes, and can the data be trusted?

Screening, emergency protocols, and person-centered care – just some of the ways healthcare professionals can identify and support people at increased risk for suicide. Click through for more.

Read our round-up of the STEP phase 3 trials of semaglutide 2.4 mg in people with obesity, plus the SELECT cardiovascular outcomes trial.

Health psychologist Michael Vallis talks about the impact of the COVID-19 pandemic on people with diabetes, and how clinicians can help (19:02).

Sharon Tovey joins Editorial Board member Lori Berard to compare and contrast how nurses are making the difference to people with diabetes in the UK and North America, respectively (14:51).

Read our overview of the SURPASS trials of the dual GLP-1/GIP receptor agonist tirzepatide in people with type 2 diabetes, plus the SURMOUNT trials in people with obesity.

Listen to Sanjay Kalra, John Wilding and Lori Berard reflecting on their research highlights of this year’s virtual 56th EASD Annual Meeting (39:05).

William Polonsky discusses the problem of people being disengaged with their diabetes, why this issue is so critical yet remains so understudied, and what healthcare professionals can do in the clinic to encourage engagement (19:09).

Kirsty Winkley discusses why people with diabetes can find it so challenging to take medications optimally and consistently, and what healthcare providers can do to help (24:50).

Thomas Kubiak discusses the psychosocial considerations when working with people using diabetes technology to manage their diabetes (16:14).